Literature DB >> 32690542

Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.

Michele Carbone1, J William Harbour2, James Brugarolas3, Angela Bononi4, Ian Pagano4, Anwesha Dey5, Thomas Krausz6, Harvey I Pass7, Haining Yang4, Giovanni Gaudino4.   

Abstract

Among more than 200 BAP1-mutant families affected by the "BAP1 cancer syndrome," nearly all individuals inheriting a BAP1 mutant allele developed one or more malignancies during their lifetime, mostly uveal and cutaneous melanoma, mesothelioma, and clear-cell renal cell carcinoma. These cancer types are also those that, when they occur sporadically, are more likely to carry somatic biallelic BAP1 mutations. Mechanistic studies revealed that the tumor suppressor function of BAP1 is linked to its dual activity in the nucleus, where it is implicated in a variety of processes including DNA repair and transcription, and in the cytoplasm, where it regulates cell death and mitochondrial metabolism. BAP1 activity in tumor suppression is cell type- and context-dependent. BAP1 has emerged as a critical tumor suppressor across multiple cancer types, predisposing to tumor development when mutated in the germline as well as somatically. Moreover, BAP1 has emerged as a key regulator of gene-environment interaction.This article is highlighted in the In This Issue feature, p. 1079. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32690542      PMCID: PMC8006752          DOI: 10.1158/2159-8290.CD-19-1220

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   38.272


  176 in total

1.  The loss of BAP1 protein expression predicts poor prognosis in patients with nonmetastatic clear cell renal cell carcinoma with inferior vena cava tumor thrombosis.

Authors:  Suguru Oka; Naoko Inoshita; Yuji Miura; Ryosuke Oki; Yu Miyama; Shoichi Nagamoto; Kohei Ogawa; Kazushige Sakaguchi; Chihiro Kondoh; Kazuhiro Kurosawa; Shinji Urakami; Toshimi Takano; Toshikazu Okaneya
Journal:  Urol Oncol       Date:  2018-05-28       Impact factor: 3.498

2.  Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status.

Authors:  Marie Schoumacher; Stéphanie Le Corre; Alexandre Houy; Eskeatnaf Mulugeta; Marc-Henri Stern; Sergio Roman-Roman; Raphaël Margueron
Journal:  Nat Med       Date:  2016-06-07       Impact factor: 53.440

3.  Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1.

Authors:  Shahram Misaghi; Søren Ottosen; Anita Izrael-Tomasevic; David Arnott; Mohamed Lamkanfi; James Lee; Jinfeng Liu; Karen O'Rourke; Vishva M Dixit; Angus C Wilson
Journal:  Mol Cell Biol       Date:  2009-02-02       Impact factor: 4.272

4.  Stabilization and targeting of INO80 to replication forks by BAP1 during normal DNA synthesis.

Authors:  Han-Sae Lee; Shin-Ai Lee; Shin-Kyoung Hur; Jeong-Wook Seo; Jongbum Kwon
Journal:  Nat Commun       Date:  2014-10-06       Impact factor: 14.919

5.  Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary.

Authors:  Tilmann Bochtler; Volker Endris; Anna Reiling; Jonas Leichsenring; Michal R Schweiger; Sebastian Klein; Fabian Stögbauer; Benjamin Goeppert; Peter Schirmacher; Alwin Krämer; Albrecht Stenzinger
Journal:  J Natl Compr Canc Netw       Date:  2018-06       Impact factor: 11.908

6.  Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases.

Authors:  Robert Pilarski; Colleen M Cebulla; James B Massengill; Karan Rai; Thereasa Rich; Louise Strong; Barbara McGillivray; Mary-Jill Asrat; Frederick H Davidorf; Mohamed H Abdel-Rahman
Journal:  Genes Chromosomes Cancer       Date:  2013-11-15       Impact factor: 5.006

7.  BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.

Authors:  Michele Carbone; Laura Korb Ferris; Francine Baumann; Andrea Napolitano; Christopher A Lum; Erin G Flores; Giovanni Gaudino; Amy Powers; Peter Bryant-Greenwood; Thomas Krausz; Elizabeth Hyjek; Rachael Tate; Joseph Friedberg; Tracey Weigel; Harvey I Pass; Haining Yang
Journal:  J Transl Med       Date:  2012-08-30       Impact factor: 5.531

8.  Loss of BAP1 function leads to EZH2-dependent transformation.

Authors:  Lindsay M LaFave; Wendy Béguelin; Richard Koche; Matt Teater; Barbara Spitzer; Alan Chramiec; Efthymia Papalexi; Matthew D Keller; Todd Hricik; Katerina Konstantinoff; Jean-Baptiste Micol; Benjamin Durham; Sarah K Knutson; John E Campbell; Gil Blum; Xinxu Shi; Emma H Doud; Andrei V Krivtsov; Young Rock Chung; Inna Khodos; Elisa de Stanchina; Ouathek Ouerfelli; Prasad S Adusumilli; Paul M Thomas; Neil L Kelleher; Minkui Luo; Heike Keilhack; Omar Abdel-Wahab; Ari Melnick; Scott A Armstrong; Ross L Levine
Journal:  Nat Med       Date:  2015-10-05       Impact factor: 53.440

Review 9.  Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer.

Authors:  Pranavi Koppula; Yilei Zhang; Li Zhuang; Boyi Gan
Journal:  Cancer Commun (Lond)       Date:  2018-04-25

10.  BAP1 links metabolic regulation of ferroptosis to tumour suppression.

Authors:  Yilei Zhang; Jiejun Shi; Xiaoguang Liu; Li Feng; Zihua Gong; Pranavi Koppula; Kapil Sirohi; Xu Li; Yongkun Wei; Hyemin Lee; Li Zhuang; Gang Chen; Zhen-Dong Xiao; Mien-Chie Hung; Junjie Chen; Peng Huang; Wei Li; Boyi Gan
Journal:  Nat Cell Biol       Date:  2018-09-10       Impact factor: 28.824

View more
  44 in total

Review 1.  The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.

Authors:  Nirosha D Perera; Aaron S Mansfield
Journal:  Curr Oncol Rep       Date:  2022-06-03       Impact factor: 5.075

2.  Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.

Authors:  Lu Wang; Noah Warren Birch; Zibo Zhao; Carson Meredith Nestler; Alexander Kazmer; Anthony Shilati; Alisha Blake; Patrick Alexander Ozark; Emily Jane Rendleman; Didi Zha; Caila Ann Ryan; Marc Alard Jonathan Morgan; Ali Shilatifard
Journal:  Nat Cancer       Date:  2021-05-25

3.  BAP1 Immunostain Status in Intraocular Biopsy Specimens for Uveal Melanoma Highly Correlates with Other Prognostic Markers.

Authors:  Cristiane M Ida; Jose Pulido; Patricia T Greipp; Joaquin J Garcia; Timothy W Olsen; Lauren Dalvin; Diva Regina Salomão
Journal:  Ocul Oncol Pathol       Date:  2021-11-15

4.  BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene × environment interaction with asbestos.

Authors:  Flavia Novelli; Angela Bononi; Qian Wang; Fang Bai; Simone Patergnani; Franz Kricek; Ellinor Haglund; Joelle S Suarez; Mika Tanji; Ronghui Xu; Yasutaka Takanishi; Michael Minaai; Sandra Pastorino; Paul Morris; Greg Sakamoto; Harvey I Pass; Haithem Barbour; Giovanni Gaudino; Carlotta Giorgi; Paolo Pinton; Jose N Onuchic; Haining Yang; Michele Carbone
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-30       Impact factor: 11.205

5.  Analysis of uveal melanomas and paired constitutional DNA for exclusion of a BAP1-tumor predisposition syndrome.

Authors:  Yasaman Arjmand Abbassi; Claudia Le Guin; Norbert Bornfeld; Nikolaos E Bechrakis; Michael Zeschnigk; Dietmar R Lohmann
Journal:  Fam Cancer       Date:  2022-08-03       Impact factor: 2.446

6.  Genomic landscape of pleural and peritoneal mesothelioma tumours.

Authors:  Stefanie Hiltbrunner; Zoe Fleischmann; Ethan S Sokol; Martin Zoche; Emanuela Felley-Bosco; Alessandra Curioni-Fontecedro
Journal:  Br J Cancer       Date:  2022-09-22       Impact factor: 9.075

Review 7.  Roles and mechanisms of BAP1 deubiquitinase in tumor suppression.

Authors:  Louis Masclef; Oumaima Ahmed; Benjamin Estavoyer; Bruno Larrivée; Nathalie Labrecque; Anastasia Nijnik; El Bachir Affar
Journal:  Cell Death Differ       Date:  2021-01-18       Impact factor: 12.067

8.  Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma.

Authors:  Dario P Anobile; Paolo Bironzo; Francesca Picca; Marcello F Lingua; Deborah Morena; Luisella Righi; Francesca Napoli; Mauro G Papotti; Alessandra Pittaro; Federica Di Nicolantonio; Chiara Gigliotti; Federico Bussolino; Valentina Comunanza; Francesco Guerrera; Alberto Sandri; Francesco Leo; Roberta Libener; Pablo Aviles; Silvia Novello; Riccardo Taulli; Giorgio V Scagliotti; Chiara Riganti
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

9.  Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma.

Authors:  Hélène Brossel; Alexis Fontaine; Clotilde Hoyos; Majeed Jamakhani; Mégane Willems; Malik Hamaidia; Luc Willems
Journal:  Cancers (Basel)       Date:  2021-06-27       Impact factor: 6.639

Review 10.  Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma.

Authors:  Stefanie Hiltbrunner; Laura Mannarino; Michaela B Kirschner; Isabelle Opitz; Angelica Rigutto; Alexander Laure; Michela Lia; Paolo Nozza; Antonio Maconi; Sergio Marchini; Maurizio D'Incalci; Alessandra Curioni-Fontecedro; Federica Grosso
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.